Evidence: well sourced. Imported from the supplied 65-Case Master Edition, dated September 19, 2026. Source links and classifications are retained as an attributed case account; import is not an independent source review.

Case at a glance

Case number
051
Date / range
2025 sale process
Sector
Consumer genetics and commercial data
Genetic asset
Genetic database, stored samples, and privacy commitments
Security principle
Corporate-Continuity Risk

Event summary

23andMe's 2025 Chapter 11 sale process turned genetic privacy into a bankruptcy-governance question: data and stored samples can outlive the company relationship in which users originally provided them.

Source: oag.dc.gov — 23andMe Bankruptcy And Data Stewardship source 1.

Source: attorneygeneral.gov — 23andMe Bankruptcy And Data Stewardship source 2.

Source: restructuring.ra.kroll.com — 23andMe Bankruptcy And Data Stewardship source 3.

The case in context

The 2025 bankruptcy process raised a continuity question: which commitments travel with genetic data and stored samples when control changes? The supplied record distinguishes the earlier bidding stage from the later TTAM transaction, rather than treating an initial bidder as the final owner.

The relevant assets are not limited to account records. Sample custody, research permissions, deletion processes, and obligations of a successor can each require separate treatment. Bankruptcy does not automatically make private data public, while a general promise to honor policies does not explain every future-use decision.

Acquisition and processing

consumer sample/data → long-lived database → financial distress → bankruptcy sale → successor control → continuity or reinterpretation of privacy commitments

The sequence of events

  1. consumer sample/data
  2. long-lived database
  3. financial distress
  4. bankruptcy sale
  5. successor control
  6. continuity or reinterpretation of privacy commitments

What became inferable or exposed

Genetic database, stored samples, and privacy commitments

23andMe's 2025 Chapter 11 sale process turned genetic privacy into a bankruptcy-governance question: data and stored samples can outlive the company relationship in which users originally provided them.

Security dimensions

Confidentiality

The confidentiality question concerns genetic database, stored samples, and privacy commitments. Exposure and further inference must be distinguished from the fact of collection or availability.

Integrity

The integrity question is whether the described material, permissions, processing, or interpretation can be relied upon. Corporate-Continuity Risk identifies the particular boundary examined here.

Availability

Access and continuity are assessed for the described event; potential effects are not presented as confirmed outages or losses.

Provenance

The relevant chain follows genetic database, stored samples, and privacy commitments through the stages shown below. Missing public detail is not proof that internal records did not exist.

GeneticSecurity.org analysis

Genetic Exposure Radius

Not assessed

No single level is assigned where the supplied dossier gives a range, conditional outcome, or broad institutional consequence. The affected parties and proposed assessment are shown separately.

Confidence: not assigned. Classification: GeneticSecurity.org analysis.

Genetic Persistence Risk

Not assessed

Persistence depends on the specific biological material or information retained. A potential effect is not treated as an observed genomic disclosure.

Confidence: not assigned. Classification: GeneticSecurity.org analysis.

Genetic Provenance Integrity

Not assessed

A numeric provenance level is not inferred from the existence of a source or court record. It requires evidence of the relevant custody and processing controls.

Confidence: not assigned. Classification: GeneticSecurity.org analysis.

Proposed classification and its limits

Suggested GER: GER-3/4. Suggested GPR: GPR-5. Suggested GPI: GPI-3/4 if custody and transfer are documented.

These are proposed classifications from the supplied case dossier. Conditional scores describe an assumed exposure; they are not evidence that it occurred. A single numeric value is left unassigned when the asset or outcome is not sufficiently bounded.

What this case does not prove

A bankruptcy filing does not automatically make data public or erase privacy law. Likewise, a promise to honor existing policies does not answer every future-use question.

Mitigations and lessons

  • Privacy-by-design sale covenants
  • Independent ombudsman
  • Affirmative consent for material purpose change
  • Deletion and sample-destruction pathways
  • Successor audits
  • Escrowed records
  • Insolvency planning before crisis

Primary sources

Secondary sources

No additional source listed. See the evidence notes for limitations.

Policy and standards

Genetic Security Policy and Standards

Review and correction history

Source edition: September 19, 2026. Imported case account; no substantive corrections recorded.

Correction policy and log

Cite this case

GS-CASE-051. 23andMe Bankruptcy: Can Genetic Consent Survive a Corporate Sale?. GeneticSecurity.org. https://geneticsecurity.org/cases/051-23andme-bankruptcy-genetic-data-sale/